Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more
Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥833.94K) by net assets (CN¥1.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chongqing Pharscin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Pharscin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Shentong Metro Co Ltd
SHG:600834
|
-0.012x |
|
Electrovaya Inc.
NASDAQ:ELVA
|
0.276x |
|
Shenwu Energy Saving Co Ltd
SHE:000820
|
-0.017x |
|
Euglena Co. Ltd
F:8EG
|
0.017x |
|
Bharat Bijlee Limited
NSE:BBL
|
-0.017x |
|
CFM Indosuez Wealth SA
PA:MLCFM
|
-1.211x |
|
Inflection Point Acquisition Corp. III Class A Ordinary Shares
NASDAQ:IPCX
|
-0.001x |
|
National Bankshares Inc
NASDAQ:NKSH
|
0.033x |
Annual Cash Flow Conversion Efficiency for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.66 Billion | CN¥161.77 Million | 0.097x | -28.12% |
| 2023-12-31 | CN¥1.62 Billion | CN¥219.34 Million | 0.136x | +1573.59% |
| 2022-12-31 | CN¥1.61 Billion | CN¥13.04 Million | 0.008x | -87.62% |
| 2021-12-31 | CN¥1.27 Billion | CN¥82.85 Million | 0.065x | -31.94% |
| 2020-12-31 | CN¥1.18 Billion | CN¥113.64 Million | 0.096x | +56.20% |
| 2019-12-31 | CN¥1.07 Billion | CN¥65.92 Million | 0.062x | +60.48% |
| 2018-12-31 | CN¥828.91 Million | CN¥31.80 Million | 0.038x | -66.05% |
| 2017-12-31 | CN¥719.95 Million | CN¥81.34 Million | 0.113x | -9.70% |
| 2016-12-31 | CN¥461.42 Million | CN¥57.73 Million | 0.125x | -30.78% |
| 2015-12-31 | CN¥365.71 Million | CN¥66.10 Million | 0.181x | +167.95% |
| 2014-12-31 | CN¥299.77 Million | CN¥20.22 Million | 0.067x | -65.66% |
| 2013-12-31 | CN¥240.97 Million | CN¥47.34 Million | 0.196x | -- |